VC
FULC icon

Vivo Capital’s Fulcrum Therapeutics FULC Stock Holding History

Vivo Capital’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-520,000
Closed -$2.31M – 52
2023
Q3 		$2.31M Sell
520,000
-30,000
-5% -$131K 0.25% 44
2023
Q2 		$1.81M Hold
550,000
– – 0.13% 43
2023
Q1 		$1.57M Buy
+550,000
New +$4.93M 0.11% 43

Other funds holding FULC

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Vivo Capital's FULC Position: Q4 2023 in Review

Vivo Capital sold out of Fulcrum Therapeutics (FULC) in Q4 2023, closing a stake of 520,000 shares — an estimated $2.31M sold.

Vivo Capital first reported a position in FULC in Q1 2023 and held it in 3 quarters. The position peaked at $2.31M in Q3 2023. 101 funds tracked by Wall St. Rank hold FULC as of Q4 2023.

  • Vivo Capital reported no remaining Fulcrum Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Vivo Capital sold 520,000 Fulcrum Therapeutics shares in Q4 2023, an estimated $2.31M.
  • Vivo Capital first reported a position in Fulcrum Therapeutics in Q1 2023 and held it in 3 quarters.
  • Vivo Capital's Fulcrum Therapeutics position peaked at $2.31M in Q3 2023.
  • 101 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q4 2023.

Based on Vivo Capital's 13F filing for Q4 2023, filed 7 Feb 2024.